SYNTHESIS OF BENZIMIDAZOLE DERIVATIVES
2615
Compound 10c. 1H NMR d 8.10 (d, J ¼ 5.2 Hz, 1H), 7.60 (s, 1H), 7.58 (m,
2H), 7.42 (s, 1H), 7.23 (m, 2H), 7.03 (d, J ¼ 6.0 Hz, 1H), 5.66 (s, 2H), 4.89 (q,
J ¼ 8.8 Hz, 17.2 Hz, 2H), 3.81 (s, 3H), 2.76 (t, J ¼ 7.6 Hz, 2H), 2.62 (s, 3H), 2.31
(s, 3H), 1.75 (m, 2H), 0.94 (t, J ¼ 6.8 Hz, 3H); MS m=z 508 (Mþ þ H); FT-IR
(KBr, cmꢀ1): 3056 (aromatic CꢀH stretching), 2963 (aliphatic CꢀH stretching),
=
=
1579, 1527 (aromatic C C, C N stretching), 1458 (aliphatic CꢀH bending), 1166
(CꢀO stretching), 834, 744 (aromatic CꢀH bending).
Compound 10d. 1H NMR d 8.03 (d, J ¼ 6.0 Hz, 1H), 7.61 (d, J ¼ 7.2 Hz, 1H),
7.58 (s, 1H), 7.55 (d, J ¼ 7.2 Hz, 1H), 7.41 (s, 1H), 7.23 (m, 2H), 6.88 (d, J ¼ 5.2 Hz,
1H), 5.60 (s, 2H), 4.09 (t, J ¼ 6.0 Hz, 2H), 3.80 (s, 3H), 3.48 (t, J ¼ 6.0 Hz, 2H), 3.24
(s, 3H), 2.77 (t, J ¼ 7.6 Hz, 2H), 2.62 (s, 3H), 2.27 (s, 3H), 1.97 (m, 2H), 1.75 (m, 2H),
0.95 (t, J ¼ 7.2 Hz, 3H); MS m=z 498 (Mþ þ H); FT-IR (KBr, cmꢀ1): 3038 (aromatic
=
=
CꢀH stretching), 2960 (aliphatic CꢀH stretching), 1579, 1524 (aromatic C C, C N
stretching), 1459 (aliphatic CꢀH bending), 1090 (CꢀO stretching), 832, 730
(aromatic CꢀH bending).
ACKNOWLEDGMENT
The authors thank the colleagues of the Analytical Research Department and
Dr. Reddy’s Laboratories Ltd., Integrated Product Development, Bachupally,
Hyderabad, India.
REFERENCES
1. (a) Brogden, R. N.; Heel, R. C.; Speight, T. M.; Avery, G. S. A review of its pharmaco-
logical properties and therapeutic use in anxiety. Drugs 1980, 20, 161–178; (b) Borel, A. G.;
Abbott, F. S. Metabolic profiling of clobazam, a 1,5-benzodiazepine, in rats. Drugs
Metab. Dispos. 1993, 21, 415–427.
2. Lisciani, R.; Baldini, A.; Benedetti. Acute cardiovascular toxicity of trazodone, etoperi-
done, and imipramine in rats. Arzneimittel-Forsch 1978, 28, 417–423.
3. Jerchel, D.; Fischer, H.; Kracht, M. Methods of preparing 2-aminomethyl benzimidazoles
were investigated. Ann. Chem. 1952, 575, 162–173.
4. Seppala, T.; Sayolainess, K. Effect of astemizole on human psychomotor performance.
Curr. Ther. Res. 1982, 31, 638–644.
5. Herrling, S.; Keller, H. 1-(p-Halobenzyl)-2-methylbenzimidazoles and salts. US Patent
2876233, March 3, 1959.
6. (a) Shibouta, Y.; Inada, Y.; Ojima, M.; Wada, T.; Noda, M.; Sanada, T.; Kubo, K.;
Kohara, Y.; Naka, T.; Nishikawa, K. Pharmacological profile of a highly potent and
long-acting angiotensin II receptor antagonist. J. Pharmacol. Exp. Ther. 1993, 266,
114–120; (b) Ogihara, T.; Nagano, M.; Mikami, H.; Higaki, J.; Kohara, K.; Azuma, J.
Effects of the angiotensin II receptor antagonist. Clin. Ther. 1994, 16, 74–86.
7. Hajime, E. Pyrrolyl benzimidazole derivative having acrylic acid derivative group on side
chain. JP Patent 11189594, July 13, 1999; Chem. Abstr. 1999, 131, 87912u.
8. Shaji, S.; Taro, M.; Toshio, N. M. 2,5,6-Substituted benzimidazole compound derivatives.
JP Patent 00026430, January 25, 2000; Chem. Abstr. 2000, 132, 122619y.
9. Kouba, N. R. Method of increasing the beneficial oxidation of a biological substrate with
2-amino benzimidazole derivatives. US Patent 3649530, July 1, 1970.